aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
aTyr Pharma (ATYR), a clinical stage biotechnology company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's CEO, Sanjay S. Shukla, will deliver a corporate presentation on Thursday, January 16, 2025, at 8:15am PST in San Francisco.
The company specializes in developing first-in-class medicines from its proprietary tRNA synthetase platform. Their lead therapeutic candidate, efzofitimod, is a first-in-class biologic immunomodulator being developed for interstitial lung disease treatment. The presentation will be webcasted and available on the company's website for at least 30 days afterward.
aTyr's platform focuses on unlocking therapeutic intervention points through signaling pathways driven by domains derived from all 20 tRNA synthetases, which are ancient proteins that have evolved to regulate diverse extracellular pathways in humans.
Positive
- None.
Negative
- None.
News Market Reaction – ATYR
On the day this news was published, ATYR gained 1.65%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference, which is scheduled to take place January 13 – 16, 2025, in San Francisco, CA.
Details of the presentation appear below:
Conference: 43rd Annual J.P. Morgan Healthcare Conference
Date: Thursday, January 16, 2025
Time: 8:15am PST
Location: San Francisco, CA
Format: Corporate Presentation
In addition to the presentation, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conference. A webcast of the presentation will be available on the Investor’s section of the company’s website at www.atyrpharma.com. Following the event, a replay of the presentation will be available on the aTyr website for at least 30 days. For more information, contact investorrelations@atyrpharma.com.
About aTyr
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.
Contact:
Ashlee Dunston
Director, Investor Relations and Public Affairs
adunston@atyrpharma.com
FAQ
When and where will aTyr Pharma (ATYR) present at the J.P. Morgan Healthcare Conference 2025?
What is aTyr Pharma's (ATYR) lead therapeutic candidate in development?
How can investors access aTyr Pharma's (ATYR) J.P. Morgan Healthcare Conference presentation?
What is the focus of aTyr Pharma's (ATYR) discovery platform?
What medical conditions does aTyr Pharma (ATYR) target with its therapeutics?
